EURONEXT-PAR$IPHA
Innate Pharma SA · Q3 2025 earnings
Q3 2025 earnings · · During market hours · Investor relations
Briefing
Innate Pharma reported FY2025 revenue and other income of €9.0M with a net loss of €49.2M (annual 20-F).
Full-year revenue and other income fell to €9.0 million from €20.1 million as collaboration revenue declined. Net loss was €49.2 million; cash and investments were €44.8 million, funding operations into Q3 2026. Pipeline progress on lacutamab, IPH6501, and ANKET programs continues.
- FY25 collaboration revenue €2.8M.
- Cash €44.8M; runway into Q3 2026.
- R&D focused on oncology pipeline.
- Negative equity; going-concern monitoring.
Headline financials
Revenue & EPS history
Innate Pharma SA · Revenue · Quarterly
€10.5M
Forward guidance
Clinical-stage biotech outlook centers on trial readouts, cash runway, and partnership optionality.
Tailwinds
- Pipeline milestones and enrollment.
- Collaboration or licensing potential.
- Non-dilutive funding paths.
Headwinds
- Trial failure or delay risk.
- Burn rate and dilution.
- Regulatory and competitive landscape.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 11 quarterly earnings reports · overlaid with Q3 2025
-0.6%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-0.2%
Avg return
30 days after
27%
3 / 11 earnings
Positive
+13.5%
Q4 2019
Best reaction
-8.8%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q3 2025 | -2.4% | -6.3% | -3.1% | |
| Q2 2024 | -4.2% | -2.7% | +37.6% | |
| Q4 2023 | -2.9% | +4.3% | -1.8% | |
| Q2 2023 | -3.9% | -3.7% | -3.0% | |
| Q4 2022 | -8.8% | -10.7% | -11.8% | |
| Q2 2022 | +2.8% | +0.7% | +13.5% | |
| Q4 2021 | +2.6% | +2.4% | -23.3% | |
| Q2 2021 | -0.6% | -1.7% | -7.3% | |
| Q4 2020 | +0.0% | +3.2% | -5.1% | |
| Q2 2020 | -2.6% | +1.3% | -5.1% | |
| Q4 2019 | +13.5% | +11.5% | +7.3% | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q2 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro